ANDA 65440, held by Fresenius Kabi USA. Idarubicin Hydrochloride.
As of Nov 22, 2026, ANDA 65440 (Idarubicin Hydrochloride), held by Fresenius Kabi USA, was first approved by FDA on Aug 4, 2009, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 4, 2009 | Original application | Approved | None posted |
| Idarubicin Hydrochloride5MG/5ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Discontinued |
| Idarubicin Hydrochloride10MG/10ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Discontinued |
| Idarubicin Hydrochloride20MG/20ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters